Wolf F Wieland
Overview
Explore the profile of Wolf F Wieland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1309
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Otto W, Wieland W
Urologe A
. 2020 Nov;
60(8):1039-1050.
PMID: 33201298
The question of what came first-in this case the diagnosis of prostate cancer or its therapy-seems absurd at first glance and is reminiscent of the classic metaphor-like problem that preoccupied...
3.
Breyer J, Denzinger S, Otto W, Brundl J, Gierth M, Fritsche H, et al.
Urol Int
. 2014 Sep;
93(3):311-9.
PMID: 25196313
Objective: Outcome prediction of pT3 urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC) remains challenging. The objective of our study was to determine high-risk patients with poor survival...
4.
Mayr R, May M, Burger M, Martini T, Pycha A, Dechet C, et al.
Urol Int
. 2014 Aug;
93(3):303-10.
PMID: 25139069
Objective: To identify prognostic clinical and histopathological parameters, including comorbidity indices at the time of radical cystectomy (RC), for overall survival (OS) after recurrence following RC for urothelial carcinoma of...
5.
Ganzer R, Brundl J, Koch D, Wieland W, Burger M, Blana A
World J Urol
. 2014 Apr;
33(1):99-104.
PMID: 24696277
Objective: To determine which pretreatment clinical parameters were predictive of a low prostate-specific antigen (PSA) nadir following high-intensity focused ultrasound (HIFU) treatment. Patients And Methods: Retrospective study of patients with...
6.
Hitzenbichler F, Stoehr C, Rogenhofer M, Wieland W, Ruemmele P, Hartmann A, et al.
Pathobiology
. 2013 Nov;
81(2):53-9.
PMID: 24217660
Objective: Human mouse double minute 2 (Mdm2) is essential in degrading p53 by acting as an ubiquitin ligase and therefore plays a vital role in cell cycle and survival. The...
7.
Aziz A, May M, Zigeuner R, Pichler M, Chromecki T, Cindolo L, et al.
J Urol
. 2013 Aug;
191(2):310-5.
PMID: 23973516
Purpose: We analyzed the distinct clinicopathological features and prognosis of patients with renal cell carcinoma age 40 years or less compared to a reference group of patients 60 to 70...
8.
Otto W, Denzinger S, Fritsche H, Burger M, Rossler W, Bertz S, et al.
Clin Genitourin Cancer
. 2013 Jul;
11(4):537-44.
PMID: 23850551
Background: Biomarkers could help to estimate the prognosis of solid tumors. One of the reasons that many immunohistochemical (IHC) markers are not used routinely is the high interobserver variability and...
9.
Brundl J, Schneider S, Weber F, Zeman F, Wieland W, Ganzer R
Eur Urol
. 2013 May;
65(4):802-8.
PMID: 23711540
Background: Perineural invasion is discussed as a significant route of extraprostatic extension in prostate cancer (PCa). Recent in vitro studies suggested a complex mechanism of neuroepithelial interaction. Objective: The present...
10.
Stoehr R, Taubert H, Gaisa N, Smeets D, Kneitz B, Giedl J, et al.
J Pathol
. 2013 May;
230(4):453-6.
PMID: 23661306
Recently mutations in the MED12 gene have been reported in 5.4% of prostate tumours from Caucasian patients analysed by exome sequencing (Barbieri CE, Baca SC, Lawrence MS, et al. Exome...